Get the tools used by (smart)2 investors.

Common Equity for Eli Lilly and Company

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

LLY: Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, H...

738.21 USD
Price
USD
Fair Value
Upside
711.40 - 972.53
52-week range

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on Eli Lilly and Company's Common Equity:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 20244 B8 B12 B16 B

Performance Summary
  • Eli Lilly's common equity last quarter was 14.192 billion
  • Eli Lilly's common equity for fiscal years ending December 2020 to 2024 averaged 10.047 billion.
  • Eli Lilly's operated at median common equity of 10.65 billion from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, Eli Lilly's common equity peaked in December 2024 at 14.192 billion.
  • Eli Lilly's common equity hit its 5-year low in December 2020 of 5.642 billion.
  • Eli Lilly's common equity increased in each of the last 5 fiscal years from 5.642 billion in 2020 to 14.192 billion in 2024.

How does Eli Lilly's Common Equity benchmark against competitors?

Hide this widget

We've identified the following companies as similar to Eli Lilly and Company because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

Metric Usage: Common Equity

Hide this widget
equity_common
Slug
number
Datatype
text
Format
current
Default Period
FY, Q
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Common Equity in the financials category include:

  • Machinery - This item represents the Assets of a durable nature held by the company, at their gross values, which are to be used in the production or sale of goods, sale of other goods or rendering of services rather than being held for sale. This is the residual item consisting of all the types of fixed assets not classifiable as either Land or Building.
  • Asset Management Fee - This item represents the fees earned from managing the assets of a third party. Also includes fees earned on providing banking services like check writing, credit cards and debit cards, brokerage features like buying securities and making loans on margin & the convenience of having all financial transactions listed on one monthly statement.
  • Other Revenue - This item represents the incidental revenues that are earned while performing the primary activities of the company.
  • NOPAT - Net operating profit after tax (NOPAT) is calculated as operating income multiplied by 1 minus the tax rate: NOPAT = Operating Income x (1 - Tax Rate).
View Full List

Search for metric or datapoint

Common Equity

The sum of all common equity items

Definition of Common Equity

Hide this widget

Eli Lilly reported common equity of 14.192 B for the latest quarter ending December 31, 2024 on its balance sheet.

The tables below summarizes Eli Lilly’s Common Equity and common size over the last five years:

Fiscal YearCommon EquityAssets% Assets
2020-12-315.642 B46.633 B12.1%
2021-12-318.979 B48.806 B18.4%
2022-12-3110.65 B49.49 B21.5%
2023-12-3110.772 B64.006 B16.8%
2024-12-3114.192 B78.715 B18.0%

The tables below summarizes Eli Lilly’s Common Equity and common size over the last four quarters:

Quarter EndingCommon EquityAssets% Assets
2024-03-3112.812 B63.944 B20.0%
2024-06-3013.562 B71.875 B18.9%
2024-09-3014.24 B75.607 B18.8%
2024-12-3114.192 B78.715 B18.0%

Click the link below to download a spreadsheet with an example Common Equity calculation for Eli Lilly and Company below:

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
0 K3 B6 B10.93 B2006001,0001,400

The chart above depicts the distribution of common equity for companies operating in the Healthcare sector in the Developed economic region. Over 2,480 companies were considered in this analysis, and 2,388 had meaningful values. The average common equity of companies in the sector is 371.3 M with a standard deviation of 1.148 B.

Eli Lilly and Company's Common Equity of 14.192 B is significantly outside the interquartile range and is excluded from the distribution. The following table provides additional summary stats:

Common Equity In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents2,488
Included Constituents2,388
Min-98.085 M
Max10.901 B
Median21.405 M
Mean371.3 M
Standard Deviation1.148 B

You can find companies with similar common equity using this stock screener.

All rights reserved. Terms Of Use